Spots Global Cancer Trial Database for pancreatic ductal adenocarcinoma
Every month we try and update this database with for pancreatic ductal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | NCT02042378 | Pancreatic Canc... Pancreatic Duct... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | NCT04400903 | Pancreatic Duct... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... | Activity Monito... Quality-of-Life... Questionnaire A... | 50 Years - 75 Years | OHSU Knight Cancer Institute | |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | NCT06131840 | Colorectal Neop... Carcinoma, Non-... Stomach Neoplas... Pancreatic Duct... Gastroesophagea... Small Cell Lung... | SGN-CEACAM5C | 18 Years - | Seagen Inc. | |
| Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions | NCT03486327 | Pancreatic Duct... | BR55 | 18 Years - | Bracco Diagnostics, Inc | |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma | NCT06344299 | Pancreatic Duct... | potential predi... | 75 Years - 100 Years | Fudan University | |
| A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | NCT05031494 | Melanoma Pancreatic Duct... | YH003 Toripalimab Nab-paclitaxel Gemcitabine | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| A Study of Personalized Neoantigen Cancer Vaccines | NCT03794128 | Non Small Cell ... Colorectal Canc... Gastroesophagea... Urothelial Carc... Pancreatic Duct... | Blood collectio... Blood collectio... | 18 Years - | Gritstone bio, Inc. | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | NCT03979066 | Pancreatic Duct... | Atezolizumab PEGPH20 | 18 Years - 99 Years | Columbia University | |
| Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma | NCT05048810 | Pancreatic Duct... | 68Ga-DOTA-NT-20... | 18 Years - 99 Years | Nanjing First Hospital, Nanjing Medical University | |
| Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | NCT02414100 | Pancreatic Duct... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... | Laboratory Biom... Cytology Specim... | 18 Years - | Thomas Jefferson University | |
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) | NCT03415854 | Pancreatic Canc... Pancreatic Duct... Pancreatic Aden... Pancreas Metast... Adenocarcinoma | Paricalcitol (Z... | 18 Years - | HonorHealth Research Institute | |
| CT Pancreas Perfusion | NCT00588367 | Pancreatic Duct... Chronic Pancrea... Autoimmune Panc... | Mayo Interactiv... | 18 Years - | Mayo Clinic | |
| Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | NCT04565327 | Pancreatic Duct... | Hyperpolarized ... Magnetic Resona... | 18 Years - | University of California, San Francisco | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | NCT05634720 | Pancreatic Duct... | HA Chemotherapy | 18 Years - | Duke University | |
| Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate | NCT04802993 | Pancreatic Duct... | Resection rates | - | Linkoeping University | |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | NCT06364696 | Solid Tumor | ASP4396 | 18 Years - | Astellas Pharma Inc | |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | NCT04976634 | Carcinoma, Hepa... Colorectal Neop... Pancreatic Duct... Biliary Tract N... Endometrial Neo... Esophageal Neop... | Pembrolizumab Belzutifan Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | NCT04046887 | Pancreatic Canc... Pancreatic Duct... | Lonsurf Gemcitabine Nab-Paclitaxel | 18 Years - | Indiana University | |
| Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | NCT05289830 | Pancreatic Duct... Periampullary C... | Escitalopram Placebo | 18 Years - 80 Years | Case Comprehensive Cancer Center | |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | NCT01280058 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Carboplatin Laboratory Biom... Paclitaxel Wild-type Reovi... | 18 Years - | National Cancer Institute (NCI) | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | NCT04565327 | Pancreatic Duct... | Hyperpolarized ... Magnetic Resona... | 18 Years - | University of California, San Francisco | |
| Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | NCT02570529 | Pancreatic Duct... | Albis® Placebo | 20 Years - 80 Years | Yonsei University | |
| Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | NCT03410030 | Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreas Metast... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | HonorHealth Research Institute | |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | NCT01658943 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | NCT02440958 | Pancreatic Duct... | modified FOLFIR... | 19 Years - 75 Years | Yonsei University | |
| The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | NCT05752812 | Pancreatic Aden... | 18 Years - 99 Years | Medical University of Vienna | ||
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | NCT03806309 | Pancreatic Duct... Locally Advance... Metastatic Canc... | FOLFIRI OSE2101 | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) | NCT06345599 | Pancreatic Duct... | Radiotherapy Immunotherapy:G... Chemotherapy:Al... | 18 Years - 75 Years | Second Affiliated Hospital of Soochow University | |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | NCT03525392 | Pancreatic Duct... Colorectal Canc... Gastric Cancer Squamous Cell C... Bone Cancer Advanced Cancer Recurrent Disea... Metastatic Tumo... | 177Lu-3BP-227 (... | 18 Years - | Ipsen | |
| Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) | NCT04692740 | Pancreatic Duct... | Chlorambucil, O... | 18 Years - | IRCCS San Raffaele | |
| Pancreatic Cancer Early Detection Consortium | NCT04970056 | Pancreas Cancer Pancreas Cyst Pancreatic Duct... Genetic Predisp... | 18 Years - 90 Years | Arbor Research Collaborative for Health | ||
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational Study | NCT03973736 | Pancreatic Duct... | application of ... | - 85 Years | Azienda Unità Sanitaria Locale Reggio Emilia | |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | NCT01280058 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Carboplatin Laboratory Biom... Paclitaxel Wild-type Reovi... | 18 Years - | National Cancer Institute (NCI) | |
| EUS-RFA for Unresectable Pancreatic Cancer | NCT04310111 | Pancreatic Duct... | EUS-RFA | 20 Years - 80 Years | First People's Hospital of Hangzhou | |
| Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy | NCT02570529 | Pancreatic Duct... | Albis® Placebo | 20 Years - 80 Years | Yonsei University | |
| CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | NCT03012282 | Pancreatic Duct... | Computed Tomogr... | 18 Years - | University of Washington | |
| Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery | NCT04189393 | Gastrointestina... Colorectal Canc... Pancreatic Canc... Esophageal Canc... Rectum Neoplasm Esophageal Neop... Pancreatic Duct... Colonic Neoplas... Gastrointestina... Microbiota Anastomotic Lea... | 18 Years - | Radboud University Medical Center | ||
| Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer | NCT05303090 | Pancreatic Duct... | H101 Tislelizumab lenvatinib | 18 Years - | Fudan University | |
| Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma | NCT04662112 | Pancreatic Canc... Pancreatic Duct... | NASOX | 19 Years - | Asan Medical Center | |
| Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | NCT05546853 | Pancreatic Duct... | NP137 Oxaliplatin Irinotecan Calcium levofol... 5 FU | 18 Years - | University Hospital, Grenoble | |
| A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | NCT05031494 | Melanoma Pancreatic Duct... | YH003 Toripalimab Nab-paclitaxel Gemcitabine | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | NCT00307723 | Pancreatic Canc... Pancreatic Duct... | bevacizumab 5-Fluorouracil Oxaliplatin gemcitabine External Beam R... | 18 Years - | Massachusetts General Hospital | |
| Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | NCT03404960 | Pancreatic Aden... | Niraparib + Niv... Niraparib + Ipi... | 18 Years - | University of Pennsylvania | |
| Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | NCT04634539 | Advanced Pancre... Pancreatic Canc... Pancreatic Duct... | Gemcitabine Nab-paclitaxel L-glutamine | 18 Years - | Cedars-Sinai Medical Center | |
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | NCT02440958 | Pancreatic Duct... | modified FOLFIR... | 19 Years - 75 Years | Yonsei University | |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | NCT04907851 | Advanced Solid ... | RXC004 RXC004 RXC004 Denosumab pembrolizumab | 18 Years - | Redx Pharma Plc | |
| Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | NCT01580397 | Pancreatic Duct... | INNO-206 | 18 Years - | CytRx | |
| Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | NCT04975217 | Pancreatic Duct... | Fecal Microbiot... Fecal Microbiot... Questionnaire A... Resection Therapeutic Col... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | NCT06048484 | Pancreatic Duct... | Stereotactic bo... Zimberelimab Quemliclustat Etrumadenant Modified FOLFIR... | 18 Years - | Columbia University | |
| FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 | NCT05518071 | Pancreas Adenoc... Cholangiocarcin... | CRGD-ZW800-1 Intraoperative ... | 18 Years - | Leiden University Medical Center | |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
| Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma Patients | NCT03659903 | Pancreas Cancer | pancreaticoduod... | - | The First Affiliated Hospital of Dalian Medical University | |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | NCT04257448 | Pancreas Cancer Pancreatic Aden... Pancreatic Duct... | Romidepsin Azacitidine nab-Paclitaxel Gemcitabine Durvalumab Lenalidomide ca... | 18 Years - | GWT-TUD GmbH | |
| Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer | NCT05132504 | Pancreatic Duct... | Pembrolizumab Folfirinox | 18 Years - | Baylor College of Medicine | |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | NCT04257448 | Pancreas Cancer Pancreatic Aden... Pancreatic Duct... | Romidepsin Azacitidine nab-Paclitaxel Gemcitabine Durvalumab Lenalidomide ca... | 18 Years - | GWT-TUD GmbH | |
| Pancreatic Cancer Detection Consortium | NCT06388967 | Pancreatic Canc... Pancreatic Carc... Pancreatic Aden... Pancreatic Duct... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... Pancreatic Canc... | PANcreatic canc... | 18 Years - | City of Hope Medical Center | |
| A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy | NCT05630989 | Pancreatic Duct... | combination the... combination the... combination the... combination the... | 18 Years - | Medical College of Wisconsin | |
| Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | NCT04927780 | Pancreatic Canc... Pancreatic Duct... Resectable Panc... | Leucovorin Calc... Fluorouracil Irinotecan Hydr... Oxaliplatin Resection | 18 Years - | Erasmus Medical Center | |
| Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery | NCT06214533 | Pancreatic Duct... Liver, Cancer o... | Ropivacaine 0.5... Normal Saline | 18 Years - | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) | NCT01096732 | Pancreatic Duct... | GDC-0449 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | NCT01013649 | Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Stage I Pancrea... Stage II Pancre... | 3-Dimensional C... Biospecimen Col... Capecitabine Chemotherapy Computed Tomogr... Erlotinib Hydro... Fluorouracil Gemcitabine Hyd... Intensity-Modul... Magnetic Resona... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery | NCT03687853 | Pancreatic Duct... Who Have High C... Liver Metastase... | Intrahepatic Ar... | 18 Years - 70 Years | Peking University Third Hospital | |
| A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer | NCT06079346 | Pancreatic Duct... | OT-101 mFOLFIRINOX | 18 Years - | Mateon Therapeutics | |
| A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma | NCT03444948 | Pancreatic Duct... | EUS-RFA using H... EUS | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer | NCT03899649 | Stage III Pancr... | SOC NanoKnife Syste... | 18 Years - | Angiodynamics, Inc. | |
| S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | NCT03316326 | Pancreatic Duct... | Tegafur-gimerac... Oxaliplatin Irinotecan | 20 Years - 79 Years | National Taiwan University Hospital | |
| Durvalumab and Oleclumab in Resectable PDAC | NCT06060405 | Pancreatic Duct... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Olaparib in Treating Patients With Stage IV Pancreatic Cancer | NCT02677038 | Metastatic Panc... Pancreatic Duct... Stage IV Pancre... | Olaparib | 18 Years - | M.D. Anderson Cancer Center | |
| Early Detection Initiative for Pancreatic Cancer | NCT04662879 | Hyperglycemia Diabetes Mellit... Pancreas Ductal... | Enriching New-o... Abdominal imagi... | 50 Years - 85 Years | Pancreatic Cancer Action Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
